Sanofi’s Menactra Use Expanded To Children
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.
You may also be interested in...
Phase III Menveo Beats Menactra In Teen Meningitis
Novartis will submit vaccine for U.S. and overseas approval later this year.
Phase III Menveo Beats Menactra In Teen Meningitis
Novartis will submit vaccine for U.S. and overseas approval later this year.
Generic Ambien Assaults Sanofi’s Top Line, But Lantus Growth Offsets Drop In Sales
Net sales fell 6 percent in the fourth quarter, but plummeting Ambien IR revenues are counteracted by 30 percent rise in insulin brand Lantus.